Chalcomycin: Single-crystal X-ray crystallographic analysis; biosynthetic and stereochemical correlations with other polyoxo macrolide antibiotics

Tetrahedron

Volumn 52, Issue 11, 1996, Pages 3857-3872

  Woo, Peter W K ^a   Rubin, J Ronald ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUMYCIN; CHALCOMYCIN; KITASAMYCIN DERIVATIVE; MACROLIDE; MARIDOMYCIN III; MYCINAMICIN DERIVATIVE; MYCINOLIDE IV; NEUTRAMYCIN; ROSARAMICIN; UNCLASSIFIED DRUG;

ARTICLE; DRUG STRUCTURE; PRIORITY JOURNAL; STEREOCHEMISTRY; X RAY CRYSTALLOGRAPHY;

EID: 0030009686     PISSN: 00404020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0040-4020(96)00052-X     Document Type: Article

References (49)

1. (a) O'Hagan, D. Nat. Prod. Rep. 1995, 12, 1.
2. (b) O'Hagan, D. Nat. Prod. Rep. 1989, 6, 205.
3. (c) Macrolide Antibiotics, Chemistry, Biology, and Practice. Omura, S., Ed.; Academic Press, Inc.: New York, 1984.
4. (a) Katz, L.; Donadio, S. Annu Rev. Microbiol. 1993, 47, 875.
5. (b) Donadio, S.; Staver, M. J.; McAlpine, J. B.; Swanson, S. J.; Katz, L. Science, 1991, 252, 675.
6. (c) Leadlay, P. F.; Staunton, J.; Aparicio, J. F.; Bevitt, D. J.; Caffrey, P.; Cortes, J.; Marsden, A.; Roberts, G. A. Biochem. Soc. Transactions. 1993, 21, 218.
7. (d) Marsden, A. F. A.; Caffrey, P.; Aparicio, J. F.; Loughran, M. S.; Staunton, J.; Leadlay, P. F. Science 1994, 263, 378.
8. (e) Cane, D. E. Science 1994, 263, 338-340.
9. (a) Kirst, H. A. Prog. Med. Chem. 1993,30, 57.
10. (b) Kirst, H. A. Prog. Med. Chem. 1994, 31, 57.
11. Jordan, D. C. In Antibiotics, I; Gottlieb, D.; Shaw, P.D., Eds.; Springer-Verlag: 1967; p. 446-450.
12. Woo, P. W. K.; Dion, H. W.; Bartz, Q. R. J. Am. Chem. Soc. 1964, 86, 2726.
13. Woo, P. W. K.; Dion, H. W.; Johnson, L. F. J. Am. Chem. Soc. 1962, 84, 1066.
14. Dion, H. W.; Woo, P. W. K.; Bartz, Q. R. J. Am. Chem. Soc. 1962, 84, 880.
15. Woo, P. W. K.; Dion, H. W.; Durham, L; Mosher, H. S. Tetrahedron Lett. 1962, 735.
16. (a) Hayashi, M; Ohno, M; Satoi, S. J. Chem. Soc. Chem. Commun. 1980, 119.
17. (b) Kinoshita, K.; Satoi, S.; Hayashi, M.; Harada, K.; Suzuki, M.; Nakatsu, K. J. Antibiotics (Tokyo). 1985, 38, 522.
18. (a) Kinoshita, K.; Satoi, S.; Hayashi, M.; Nakatsu, K. J. Antibiotics (Tokyo) 1989, 42, 1003.
19. (b) Ganguly, A. K.; Liu, Y. T.; McPhail, A. T.; Sarre, O. J. Chem. Soc. Chem. Commun. 1982, 853.
20. (c) Hayashi, M; Kinoshita, K; Satoi, S; Nakatsu, K. J. Antibiotics (Tokyo) 1982, 35, 1243.
21. Ganguly, A. K.; Liu, Y. T.; Sarre, O.; Jaret, R. S.; McPhail, A. T.; Onan, K. K. J. Tetrahedron Lett. 1980, 21, 4699.
22. (a) Omura, S.; Matsubara, H.; Nakagawa, A;.; Furusaki, A.; Matsumoto, T. J. Antibiotics (Tokyo). 1980, 33, 915.
23. (b) Jones, N.D.; Chaney, M.O.; Kirst, H.A.; Wild, G.M.; Baltz, R.H.; Hamill, R.L.; Paschal, J.W. ibid. 1982, 35, 420.
24. Kamiya, K.; Wada, Y.; Kondo, K. Chem. Pharm. Bull. 1978, 26, 1753.
25. (a) Hiramatsu, M.; Furusaki, A.; Noda, T.; Naya, K.; Tomie, Y.; Nitta, I.; Watanabe, T.; Take, T.; Abe J.; Omura, S.; Hata, T. Bull. Chem. Soc. Japan 1970, 43, 1966.
26. (b) Muroi, M.; Kishi, T. Chem. Pharm. Bull. 1978, 26 , 2718.
27. Clardy, J.; Finer-Moore, J.; Weiler, L.; Wiley, D. C. Tetrahedron, Suppl. 1981, 37, 91.
28. Mitscher, L. A.; Kunstmann, M. P. Experientia 1969, 25, 12.
29. (a) Cullen, W. P.; Hauske, J. R.; Maeda, H.; Tone, J. U.S. Patents 4,835,141, May 30, 1989.
30. (b) Hauske, J. R.; Dibrino, J.; Guadliana, M.; Kostek, G. J. Org. Chem. 1986, 51, 2808.
31. Mizobuchi, S.; Mochizuki, J.; Soga, H.; Tanba, H.; Inoue, H. J. Antibiotics 1986, 39, 1776.
32. Chatterjee, S.; Reddy, G. C. S.; Franco, C. M. M.; Rupp, R. H.; Ganguli, B. N.; Fehlhaber, H.-W.; Kogler, H. J. Antibiotics. 1987, 40, 1368.
33. (a) Celmer, W. D. Pure Appl. Chem. 1971, 28, 413.
34. (b) Cane, D. E.; Celmer, W. D.; Westley, J. W. J. Am. Chem. Soc. 1983, 105, 3594.
35. (c) In structure, model A (21, Fig. 4) is identical to Celmer's model for 14-membered macrolides; in function, model A "serves all the known 12-and 14-membered ring macrolides and includes chiral centers at C-3, C-5, C-6, and C-8 in 16-membered ring macrolides" (page 3595, reference 20b).
36. (a) It has been demonstrated that C6 hydroxylation of 6-dEB (23) occurred with configuration retention, late in the biosynthetic pathway (Corcoran, J. W.; Vygantas, A. M. Biochemistry 1982, 21, 263).
37. (b) Similarly, for the stereochemical models 2, 21 and 22, any "extra" hydroxyl group at a given chiral center are considered introduced with retention of configuration at a late stage (after cycle 6 in Fig. 5b).
38. (c) Seno, E.T.; Baltz, R.H. Antimicrob. Agents Chemother. 1981, 20, 370.
39. (d) Butte, J.C.; Corcoran, J.W. Abstracts, Federation Proceedings 1962, 21, 89.
40. 1b and is analogous to the epoxide structure of the 14-membered oleandomycin (24; Fig. 4). (b) The established chirality at C8 of chalcomycin allows assignment to the corresponding center in the other neutral 16-membered macrolides (15,17, Fig. 3) with certainty.
41. 2e
42. Cane, D.E.; Liang, T.-C.; Taylor, P.B.; Chang, C.; Yang, C.-C. J. Am. Chem. Soc. 1986, 108, 4957.
43. (a) Cane, D. E.; Yang, C.-C. J. Am. Chem. Soc. 1987, 109, 1255.
44. (b) Cane, D. E.; Lambalot, R. H.; Prabhakaran, P. C.; Ott, W. R. J. Am. Chem. Soc. 1993, 115, 522.
45. Yue, S.; Duncan, J. S.; Yamamoto, Y.; Hutchinson, C. R. J. Am. Chem. Soc. 1987, 109, 1253.
46. (a) Some crystallographic properties of chalcomycin, reported previously (Krc. J., Jr.; Scott, R. B. Microscope 1975, 23, 15; C.A. 1975, 83. 51293u), were particularly useful in determining the molecular weight of the compound, (b) A previous attempted single-crystal X-ray crystallographic analysis of chalcomycin as its heavy atom derivative was unsuccessful. The derivative, bis-bromoacetyl chalcomycin (crystals from methanol, mp 114-119 °C) lost its crystallinity under the X-ray beam (George A. Sim, unpublished results, 1966).
47. (a) Some crystallographic properties of chalcomycin, reported previously (Krc. J., Jr.; Scott, R. B. Microscope 1975, 23, 15; C.A. 1975, 83. 51293u), were particularly useful in determining the molecular weight of the compound, (b) A previous attempted single-crystal X-ray crystallographic analysis of chalcomycin as its heavy atom derivative was unsuccessful. The derivative, bis-bromoacetyl chalcomycin (crystals from methanol, mp 114-119 °C) lost its crystallinity under the X-ray beam (George A. Sim, unpublished results, 1966).
48. (a) Some crystallographic properties of chalcomycin, reported previously (Krc. J., Jr.; Scott, R. B. Microscope 1975, 23, 15; C.A. 1975, 83. 51293u), were particularly useful in determining the molecular weight of the compound, (b) A previous attempted single-crystal X-ray crystallographic analysis of chalcomycin as its heavy atom derivative was unsuccessful. The derivative, bis-bromoacetyl chalcomycin (crystals from methanol, mp 114-119 °C) lost its crystallinity under the X-ray beam (George A. Sim, unpublished results, 1966).
49. Deposited at the Cambridge Crystallographic Data Centre.